Keshav Narain, MD
Ophthalmology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 33
- 9 carriers
- Office
- 1
Offices
1 location
Looking this up.
Hospitals listed: Good Samaritan Hospital. That is not proof they admit you there this week.
Plans that list them
33 plans · 9 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Narain’s office at (408) 294-3534 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
33 of 33 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$1,041,043
Medicare paid this office $1,041,043 for 442 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, faricimab-svoa, 0.1 mg | 22 | $104,721 | None |
| Laser repair to improve eye fluid flow | 184 | $84,582 | $250 |
| Established patient complete exam of visual system | 354 | $81,392 | $115 |
| Measurement of retinal and optic nerve function | 327 | $74,740 | $134 |
| Nerve test | 323 | $42,522 | $77 |
See all 18 services
| Injection, faricimab-svoa, 0.1 mg | 22 | $104,721 | None |
| Laser repair to improve eye fluid flow | 184 | $84,582 | $250 |
| Established patient complete exam of visual system | 354 | $81,392 | $115 |
| Measurement of retinal and optic nerve function | 327 | $74,740 | $134 |
| Nerve test | 323 | $42,522 | $77 |
| Placement of amniotic membrane on eye surface for wound healing | 11 | $26,220 | $1,311 |
| Exam of visual field with extended testing | 245 | $24,415 | $62 |
| Imaging of optic nerve | 288 | $16,951 | $36 |
| Injection of drug into eye | 38 | $15,934 | $111 |
| Return visit (30+ min) | 94 | $14,941 | $129 |
| Imaging of retina | 165 | $12,696 | $41 |
| Photography of the retina | 198 | $8,730 | $35 |
| Short return visit (20+ min) | 74 | $7,733 | $88 |
| New patient complete exam of visual system | 58 | $7,469 | $129 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 29 | $6,855 | $185 |
| Short return visit | 107 | $6,336 | $47 |
| Imaging of front third of eye | 54 | $1,621 | $29 |
| Injection, bevacizumab, 10 mg | 11 | $1,546 | None |
Procedures Medicare counted
| Cataract surgery | 11 | More than 32% of doctors who do this |
Who their Medicare patients are
442 Original Medicare patients in 2024. Average age 76 · Under 65 3% · 85 and older 18% · Women 57% · Also on Medicaid 33% · Health risk score 1.21. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 44% · Coronary heart disease 27% · Chronic kidney disease 23% · Atrial fibrillation 15% · Heart failure 14% · Cancer 11% · Depression 11% · COPD 10% · Dementia 8% · Stroke 6%.
The office billed $3,329,221, Medicare allowed $1,336,396 and paid $1,041,043; for 10,321 services of 47 kinds; $585,454 of it was for drugs given in the office and $455,589 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 442 | 10,321 | 76 | 1.21 | $3,329,221 | $1,041,043 |
| 2023 | 456 | 7,719 | 77 | 1.14 | $2,488,185 | $639,999 |
| 2022 | 470 | 5,342 | 77 | 1.22 | $2,379,383 | $632,320 |
| 2021 | 480 | 4,906 | 77 | 1.18 | $1,894,437 | $553,986 |
| 2020 | 471 | 4,610 | 77 | 1.37 | $1,733,977 | $484,021 |
| 2019 | 563 | 6,023 | 76 | 1.30 | $2,203,462 | $621,086 |
| 2018 | 474 | 5,024 | 76 | 1.29 | $1,740,253 | $526,366 |
| 2017 | 421 | 4,934 | 75 | 1.36 | $1,372,740 | $463,533 |
| 2016 | 439 | 5,185 | 75 | 1.34 | $1,382,800 | $476,787 |
| 2015 | 481 | 4,139 | 75 | 1.40 | $1,132,303 | $412,977 |
| 2014 | 477 | 3,430 | 75 | 1.35 | $900,580 | $320,248 |
| 2013 | 414 | 3,474 | 75 | 1.40 | $1,005,286 | $334,948 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 19 services
| Established patient complete exam of visual system | 360 | $88,425 | $117 |
| Injection, aflibercept, 1 mg | 33 | $79,451 | None |
| Injection, faricimab-svoa, 0.1 mg | 17 | $78,223 | None |
| Measurement of retinal and optic nerve function | 339 | $75,421 | $130 |
| Laser repair to improve eye fluid flow | 153 | $60,414 | $228 |
| Nerve test | 338 | $41,493 | $72 |
| Return visit (30+ min) | 159 | $28,454 | $114 |
| Exam of visual field with extended testing | 218 | $21,261 | $58 |
| Injection of drug into eye | 51 | $17,470 | $109 |
| Imaging of retina | 213 | $17,225 | $39 |
| Photography of the retina | 309 | $14,832 | $35 |
| Imaging of optic nerve | 269 | $12,952 | $34 |
| Short return visit | 180 | $10,979 | $47 |
| New patient complete exam of visual system | 66 | $8,389 | $127 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 41 | $7,539 | $148 |
| Short return visit (20+ min) | 38 | $3,755 | $83 |
| Imaging of front third of eye | 68 | $2,023 | $29 |
| New patient visit (45+ min) | 14 | $1,868 | $133 |
| Injection, bevacizumab, 10 mg | 19 | $1,700 | None |
2022: 19 services
| Injection, aflibercept, 1 mg | 33 | $148,238 | None |
| Laser repair to improve eye fluid flow | 175 | $74,422 | $240 |
| Measurement of retinal and optic nerve function | 325 | $65,466 | $123 |
| Return visit (30+ min) | 255 | $64,117 | $111 |
| Established patient complete exam of visual system | 264 | $50,060 | $117 |
| Nerve test | 342 | $43,004 | $70 |
| Placement of amniotic membrane on eye surface for wound healing | 13 | $24,745 | $1,547 |
| Exam of visual field with extended testing | 198 | $19,637 | $59 |
| Injection of drug into eye | 55 | $18,488 | $107 |
| Imaging of retina | 194 | $15,236 | $39 |
| Photography of the retina | 331 | $15,152 | $35 |
| Imaging of optic nerve | 278 | $15,083 | $34 |
| Short return visit | 207 | $12,882 | $45 |
| New patient complete exam of visual system | 65 | $8,119 | $125 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 44 | $7,520 | $132 |
| Short return visit (20+ min) | 80 | $6,822 | $76 |
| Injection, bevacizumab, 10 mg | 37 | $3,329 | None |
| New patient visit (45+ min) | 20 | $2,660 | $133 |
| Imaging of front third of eye | 69 | $2,006 | $27 |
2021: 21 services
| Injection, aflibercept, 1 mg | 30 | $85,939 | None |
| Measurement of retinal and optic nerve function | 324 | $70,224 | $138 |
| Laser repair to improve eye fluid flow | 158 | $66,350 | $246 |
| Return visit (30+ min) | 273 | $66,060 | $121 |
| Established patient complete exam of visual system | 309 | $51,968 | $109 |
| Nerve test | 341 | $42,179 | $73 |
| Exam of visual field with extended testing | 193 | $18,683 | $59 |
| Imaging of optic nerve | 305 | $17,558 | $35 |
| Injection of drug into eye | 46 | $13,645 | $111 |
| Photography of the retina | 263 | $12,911 | $38 |
| Imaging of retina | 138 | $11,943 | $40 |
| Short return visit | 177 | $11,406 | $50 |
| New patient complete exam of visual system | 84 | $9,946 | $118 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 46 | $8,872 | $127 |
| Short return visit (20+ min) | 51 | $5,976 | $83 |
| Removal of recurring cataract in lens capsule using a laser | 13 | $4,996 | $357 |
| Pattern recording of retinal electrical responses to external stimuli with interpretation and report | 65 | $4,412 | $64 |
| Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye | 14 | $3,924 | $280 |
| New patient visit (45+ min) | 20 | $2,584 | $129 |
| Injection, bevacizumab, 10 mg | 27 | $2,554 | None |
| Imaging of front third of eye | 66 | $1,976 | $28 |
2020: 20 services
| Injection, aflibercept, 1 mg | 28 | $108,572 | None |
| Established patient complete exam of visual system | 410 | $96,243 | $112 |
| Laser repair to improve eye fluid flow | 173 | $66,592 | $233 |
| Pattern recording of retinal electrical responses to external stimuli with interpretation and report | 309 | $36,090 | $79 |
| Nerve test | 323 | $33,472 | $68 |
| Imaging of retina | 251 | $16,946 | $38 |
| Exam of visual field with extended testing | 187 | $14,746 | $56 |
| Photography of the retina | 249 | $14,545 | $43 |
| Injection of drug into eye | 51 | $13,759 | $101 |
| Imaging of optic nerve | 278 | $12,877 | $33 |
| New patient complete exam of visual system | 104 | $10,780 | $104 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 70 | $9,162 | $109 |
| Destruction of leaking blood vessels of retina using laser | 12 | $4,559 | $326 |
| Established patient problem focused exam of visual system | 42 | $3,689 | $84 |
| Injection, bevacizumab, 10 mg | 24 | $3,493 | None |
| Imaging of front third of eye | 106 | $3,153 | $29 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 132 | $3,050 | $19 |
| Measurement of retinal and optic nerve function | 19 | $2,678 | $141 |
| Short return visit | 29 | $1,217 | $41 |
| Ultrasound scan of cornea to determine thickness | 51 | $544 | $11 |
2019: 21 services
| Injection, aflibercept, 1 mg | 30 | $135,205 | None |
| Established patient complete exam of visual system | 477 | $123,227 | $111 |
| Laser repair to improve eye fluid flow | 157 | $58,467 | $237 |
| Pattern recording of retinal electrical responses to external stimuli with interpretation and report | 377 | $47,513 | $81 |
| Nerve test | 394 | $42,312 | $69 |
| Imaging of retina | 371 | $26,949 | $39 |
| Photography of the retina | 363 | $25,254 | $49 |
| Injection of drug into eye | 57 | $17,518 | $98 |
| Exam of visual field with extended testing | 227 | $17,123 | $56 |
| New patient visit (45+ min) | 128 | $16,879 | $132 |
| Established patient problem focused exam of visual system | 129 | $16,210 | $78 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 106 | $12,760 | $92 |
| Imaging of optic nerve | 279 | $11,879 | $33 |
| New patient complete exam of visual system | 57 | $6,682 | $117 |
| Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye | 21 | $6,548 | $243 |
| Removal of recurring cataract in lens capsule using a laser | 17 | $5,816 | $306 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 173 | $4,403 | $21 |
| Measurement of retinal and optic nerve function | 27 | $4,186 | $140 |
| Injection, bevacizumab, 10 mg | 34 | $4,074 | None |
| Imaging of front third of eye | 120 | $3,939 | $29 |
| Ultrasound scan of cornea to determine thickness | 58 | $654 | $11 |
2018: 21 services
| Injection, aflibercept, 1 mg | 21 | $109,414 | None |
| Recording of retinal electrical responses to external stimuli | 343 | $71,626 | $150 |
| Established patient complete exam of visual system | 296 | $65,101 | $112 |
| Established patient problem focused exam of visual system | 324 | $43,074 | $78 |
| Laser repair to improve eye fluid flow | 129 | $42,183 | $234 |
| Nerve test | 352 | $32,821 | $66 |
| Imaging of retina | 345 | $26,629 | $39 |
| Photography of the retina | 293 | $21,306 | $55 |
| Exam of visual field with extended testing | 235 | $20,965 | $59 |
| Injection of drug into eye | 61 | $17,236 | $98 |
| New patient visit (45+ min) | 71 | $9,247 | $130 |
| Imaging of optic nerve | 168 | $7,044 | $35 |
| Injection, bevacizumab, 10 mg | 48 | $5,952 | None |
| Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye | 19 | $5,496 | $239 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 55 | $5,376 | $85 |
| New patient complete exam of visual system | 42 | $4,763 | $113 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 169 | $3,880 | $19 |
| Imaging of front third of eye | 72 | $2,559 | $28 |
| New patient visit (30+ min) | 13 | $813 | $63 |
| Short return visit (20+ min) | 12 | $555 | $46 |
| Exam of the internal drainage system of eye | 14 | $363 | $26 |
2017: 20 services
| Established patient complete exam of visual system | 315 | $65,974 | $112 |
| Recording of retinal electrical responses to external stimuli | 312 | $65,714 | $150 |
| Nerve test | 315 | $59,583 | $132 |
| Laser repair to improve eye fluid flow | 117 | $39,417 | $233 |
| Established patient problem focused exam of visual system | 254 | $34,088 | $80 |
| Exam of visual field with extended testing | 288 | $27,886 | $58 |
| Photography of the retina | 269 | $24,628 | $65 |
| Imaging of retina | 303 | $23,343 | $36 |
| Injection of drug into eye | 53 | $14,769 | $97 |
| New patient complete exam of visual system | 53 | $6,516 | $123 |
| Imaging of optic nerve | 136 | $5,544 | $34 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 53 | $4,854 | $77 |
| Short return visit (20+ min) | 69 | $4,668 | $56 |
| Return visit (30+ min) | 72 | $4,551 | $60 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 178 | $4,061 | $19 |
| New patient visit (45+ min) | 31 | $3,876 | $125 |
| Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye | 16 | $3,766 | $235 |
| Compounded drug, not otherwise classified | 30 | $3,677 | None |
| Injection, bevacizumab, 10 mg | 33 | $3,520 | None |
| Imaging of front third of eye | 75 | $2,660 | $29 |
2016: 20 services
| Established patient problem focused exam of visual system | 287 | $62,142 | $77 |
| Nerve test | 264 | $46,558 | $129 |
| Recording of retinal electrical responses to external stimuli | 247 | $45,598 | $138 |
| Return visit (30+ min) | 134 | $35,187 | $95 |
| Photography of the retina | 277 | $29,183 | $76 |
| Laser repair to improve eye fluid flow | 79 | $28,512 | $262 |
| Imaging of retina | 318 | $28,208 | $41 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 104 | $25,956 | $100 |
| Exam of visual field with extended testing | 266 | $25,520 | $59 |
| Injection of drug into eye | 74 | $17,815 | $93 |
| Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye | 20 | $8,939 | $223 |
| Injection, bevacizumab, 10 mg | 64 | $8,741 | None |
| New patient complete exam of visual system | 57 | $6,495 | $114 |
| Creation of eye fluid drainage tracts in iris using a laser, per session | 11 | $5,294 | $265 |
| Established patient complete exam of visual system | 51 | $4,651 | $91 |
| Imaging of optic nerve | 94 | $4,276 | $40 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 129 | $3,146 | $19 |
| Short return visit (20+ min) | 30 | $2,203 | $67 |
| Ultrasound scan of eye using water bath method | 12 | $2,065 | $90 |
| New patient visit (45+ min) | 16 | $2,013 | $126 |
2015: 21 services
| Established patient problem focused exam of visual system | 273 | $54,490 | $83 |
| Laser repair to improve eye fluid flow | 84 | $40,050 | $313 |
| Return visit (30+ min) | 255 | $39,752 | $90 |
| Nerve test | 230 | $39,191 | $127 |
| Imaging of retina | 358 | $32,954 | $42 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 118 | $27,224 | $99 |
| Recording of retinal electrical responses to external stimuli | 139 | $24,235 | $143 |
| Photography of the retina | 202 | $17,753 | $77 |
| Injection of drug into eye | 79 | $17,007 | $92 |
| Exam of visual field with extended testing | 166 | $12,966 | $61 |
| New patient complete exam of visual system | 63 | $7,698 | $122 |
| Injection, bevacizumab, 10 mg | 63 | $6,675 | None |
| New patient visit (45+ min) | 47 | $5,513 | $117 |
| Established patient complete exam of visual system | 45 | $5,197 | $113 |
| Exam of the internal drainage system of eye | 98 | $2,542 | $25 |
| Short return visit (20+ min) | 36 | $2,299 | $62 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 82 | $1,709 | $20 |
| Imaging of optic nerve | 26 | $1,183 | $41 |
| Unclassified biologics | 11 | $686 | None |
| Photography of content of eyes | 17 | $339 | $20 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 17 | $63 | None |
2014: 20 services
| Return visit (30+ min) | 327 | $56,259 | $93 |
| Imaging of retina | 338 | $33,080 | $41 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 126 | $28,523 | $97 |
| Injection of drug into eye | 68 | $19,313 | $91 |
| Destruction of leaking blood vessels of retina using laser | 16 | $18,168 | $956 |
| Destruction of growth of retina using a laser | 25 | $16,413 | $483 |
| Photography of the retina | 189 | $15,953 | $70 |
| Established patient problem focused exam of visual system | 152 | $14,448 | $69 |
| Nerve test | 100 | $14,385 | $134 |
| Exam of visual field with extended testing | 153 | $12,281 | $60 |
| New patient visit (45+ min) | 86 | $12,268 | $143 |
| Unclassified biologics | 52 | $6,218 | None |
| Recording of retinal electrical responses to external stimuli | 38 | $6,105 | $157 |
| Short return visit (20+ min) | 83 | $5,438 | $61 |
| Removal of recurring cataract in lens capsule using a laser | 12 | $4,198 | $323 |
| New patient visit (30+ min) | 41 | $3,330 | $81 |
| Established patient complete exam of visual system | 33 | $2,979 | $90 |
| Injection, bevacizumab, 10 mg | 32 | $2,077 | None |
| Imaging of optic nerve | 33 | $1,691 | $40 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 17 | $119 | None |
2013: 17 services
| Return visit (30+ min) | 268 | $44,592 | $87 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 123 | $33,067 | $101 |
| Imaging of retina | 287 | $32,500 | $42 |
| Destruction of leaking blood vessels of retina using laser | 19 | $28,489 | $950 |
| Injection of drug into eye | 86 | $24,989 | $93 |
| Established patient problem focused exam of visual system | 183 | $20,400 | $76 |
| Destruction of growth of retina using a laser | 29 | $19,426 | $498 |
| Photography of the retina | 165 | $15,136 | $70 |
| Injection, bevacizumab, 10 mg | 80 | $12,023 | None |
| Exam of visual field with extended testing | 93 | $7,042 | $63 |
| Short return visit (20+ min) | 92 | $6,443 | $63 |
| Examination of eye by ophthalmoscope with retinal drawing | 121 | $6,263 | $23 |
| Established patient complete exam of visual system | 41 | $4,094 | $100 |
| New patient visit (30+ min) | 43 | $3,918 | $91 |
| New patient visit (45+ min) | 24 | $2,966 | $124 |
| Imaging of optic nerve | 45 | $2,445 | $41 |
| 2d ultrasound scan of eye tissue and structures | 12 | $1,571 | $92 |
Medicaid work
$5,143 in 2024
Medicaid paid $5,143 for 1,082 billed services this clinician did in 2024, up to 46 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 306 | $1,313 |
| Electroretinography (ERG), with interpretation and report; full field (ie, ffERG, flash ERG, Ganzfeld ERG) | 171 | $1,219 |
| Trabeculoplasty by laser surgery | 35 | $1,206 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 13 | $307 |
| Visual evoked potential (VEP) checkerboard or flash testing, central nervous system except glaucoma, with interpretation and report | 171 | $297 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 122 | $223 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 104 | $222 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 36 | $171 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 112 | $142 |
| Short return visit | 12 | $44 |
| 2024 | 1,082 | 10 | 46 | $5,143 |
| 2023 | 1,498 | 11 | 37 | $5,254 |
| 2022 | 1,629 | 11 | 40 | $6,112 |
| 2021 | 1,338 | 9 | 36 | $1,975 |
| 2020 | 949 | 9 | 40 | $2,845 |
| 2019 | 1,281 | 11 | 40 | $1,699 |
| 2018 | 491 | 7 | 21 | $690 |
See the largest Medicaid services in earlier years
2023
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 342 | $1,335 |
| Electroretinography (ERG), with interpretation and report; full field (ie, ffERG, flash ERG, Ganzfeld ERG) | 221 | $1,194 |
| Trabeculoplasty by laser surgery | 12 | $698 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 182 | $429 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 150 | $399 |
| Visual evoked potential (VEP) checkerboard or flash testing, central nervous system except glaucoma, with interpretation and report | 221 | $375 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 14 | $292 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 165 | $233 |
| Return visit (30+ min) | 45 | $139 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 120 | $85 |
| Short return visit | 26 | $75 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 45 | $1,598 |
| Electroretinography (ERG), with interpretation and report; full field (ie, ffERG, flash ERG, Ganzfeld ERG) | 207 | $1,551 |
| Return visit (30+ min) | 282 | $664 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 185 | $574 |
| Visual evoked potential (VEP) checkerboard or flash testing, central nervous system except glaucoma, with interpretation and report | 252 | $370 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 152 | $263 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 141 | $256 |
| Trabeculoplasty by laser surgery | 18 | $253 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 160 | $239 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 128 | $195 |
| Short return visit | 59 | $149 |
2021
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 165 | $630 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 166 | $416 |
| Electroretinography (ERG), with interpretation and report; full field (ie, ffERG, flash ERG, Ganzfeld ERG) | 192 | $402 |
| Return visit (30+ min) | 245 | $174 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 93 | $171 |
| Visual evoked potential (VEP) checkerboard or flash testing, central nervous system except glaucoma, with interpretation and report | 212 | $95 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 91 | $66 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 159 | $22 |
| Short return visit | 15 | $0 |
2020
| Trabeculoplasty by laser surgery | 16 | $1,309 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 324 | $800 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 134 | $410 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 131 | $191 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 115 | $69 |
| Visual evoked potential (VEP) checkerboard or flash testing, central nervous system except glaucoma, with interpretation and report | 144 | $61 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 44 | $3 |
| OFF/OP EST MAY X REQ PHY/QHP | 29 | $1 |
| Electroretinography (ERG) with interpretation and report, pattern (PERG) | 12 | $0 |
2019
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 393 | $992 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 252 | $246 |
| Visual evoked potential (VEP) checkerboard or flash testing, central nervous system except glaucoma, with interpretation and report | 219 | $223 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 193 | $183 |
| Electroretinography (ERG) with interpretation and report, pattern (PERG) | 51 | $35 |
| New patient visit (45+ min) | 17 | $14 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 58 | $3 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), anterior segment, with interpretation and report, unilateral or bilateral | 12 | $3 |
| Trabeculoplasty by laser surgery | 30 | $0 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 43 | $0 |
| OFF/OP EST MAY X REQ PHY/QHP | 13 | $0 |
2018
| Visual evoked potential (VEP) checkerboard or flash testing, central nervous system except glaucoma, with interpretation and report | 67 | $137 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 95 | $129 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 93 | $123 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 61 | $109 |
| Service | 66 | $109 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 96 | $83 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 13 | $0 |
Drugs they prescribed that Part D paid
$542,182
Pharmacies billed $542,182 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,064) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
871 generic and 1,193 brand-name prescriptions · $542,182 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Restasis | 226 | $163,621 | $724 |
| Xiidra | 143 | $112,110 | $784 |
| Cequa | 90 | $58,095 | $645 |
| Xdemvy | 31 | $56,672 | $1,828 |
| Cyclosporine | 124 | $31,910 | $257 |
See all 22 drugs
| Restasis | 226 | $163,621 | $724 |
| Xiidra | 143 | $112,110 | $784 |
| Cequa | 90 | $58,095 | $645 |
| Xdemvy | 31 | $56,672 | $1,828 |
| Cyclosporine | 124 | $31,910 | $257 |
| Prednisolone Acetate | 334 | $14,953 | $45 |
| Prolensa | 33 | $11,232 | $340 |
| Brinzolamide | 66 | $9,814 | $149 |
| Simbrinza | 41 | $8,377 | $204 |
| Rhopressa | 27 | $8,347 | $309 |
| Bromfenac | 46 | $7,100 | $154 |
| Dorzolamide | 454 | $6,769 | $15 |
| Vyzulta | 11 | $5,922 | $538 |
| Azopt | 14 | $5,585 | $399 |
| Brimonidine | 169 | $2,459 | $15 |
| Ketorolac Tromethamine | 23 | $974 | $42 |
| Atropine Sulfate | 18 | $465 | $26 |
| Dorzolamide-Timolol | 32 | $322 | $10 |
| Timolol Maleate | 43 | $270 | $6 |
| Moxifloxacin | 13 | $220 | $17 |
| Prednisone | 12 | $97 | $8 |
| Latanoprost | 13 | $68 | $5 |
Year by year
| 2024 | 2,064 | 408 | 0% (0) | 58% | $542,182 |
| 2023 | 2,359 | 372 | 0% (0) | 54% | $700,068 |
| 2022 | 2,077 | 353 | 0% (0) | 57% | $615,563 |
| 2021 | 1,676 | 317 | 0% (0) | 49% | $533,277 |
| 2020 | 1,391 | 285 | 0% (0) | 48% | $492,274 |
| 2019 | 1,248 | 309 | 0% (0) | 51% | $398,551 |
| 2018 | 1,123 | 240 | 0% (0) | 57% | $350,413 |
| 2017 | 1,084 | 220 | 0% (0) | 58% | $283,647 |
| 2016 | 989 | 215 | 0% (0) | 67% | $286,486 |
| 2015 | 1,097 | 207 | 0% (0) | 56% | $249,080 |
| 2014 | 838 | 157 | None | 65% | $163,253 |
| 2013 | 612 | 117 | 0% (0) | 67% | $88,824 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 25 drugs
| Restasis | 301 | $252,664 | $839 |
| Xiidra | 119 | $112,643 | $947 |
| Cequa | 101 | $64,924 | $643 |
| Tyrvaya | 34 | $35,251 | $1,037 |
| Prolensa | 89 | $32,903 | $370 |
| Cyclosporine | 63 | $30,583 | $485 |
| Xdemvy | 12 | $22,745 | $1,895 |
| Dorzolamide | 676 | $22,623 | $33 |
| Brinzolamide | 37 | $15,048 | $407 |
| Simbrinza | 58 | $13,845 | $239 |
| Azopt | 30 | $13,139 | $438 |
| Vyzulta | 26 | $10,919 | $420 |
| Prednisolone Acetate | 266 | $9,579 | $36 |
| Bromfenac | 55 | $8,288 | $151 |
| Rhopressa | 21 | $7,726 | $368 |
| Alphagan P | 20 | $6,985 | $349 |
| Combigan | 17 | $4,845 | $285 |
| Brimonidine | 146 | $3,245 | $22 |
| Lotemax Sm | 12 | $3,094 | $258 |
| Brimonidine Tartrate-Timolol | 12 | $1,661 | $138 |
| Atropine Sulfate | 23 | $1,040 | $45 |
| Dorzolamide-Timolol | 35 | $981 | $28 |
| Latanoprost | 36 | $897 | $25 |
| Timolol Maleate | 48 | $579 | $12 |
| Moxifloxacin | 11 | $299 | $27 |
2022: 23 drugs
| Restasis | 299 | $280,938 | $940 |
| Cequa | 103 | $69,877 | $678 |
| Xiidra | 81 | $65,754 | $812 |
| Prolensa | 74 | $24,953 | $337 |
| Dorzolamide | 638 | $20,527 | $32 |
| Rhopressa | 29 | $16,486 | $568 |
| Brinzolamide | 38 | $16,183 | $426 |
| Combigan | 41 | $14,569 | $355 |
| Cyclosporine | 27 | $12,458 | $461 |
| Simbrinza | 54 | $12,265 | $227 |
| Alphagan P | 39 | $12,255 | $314 |
| Azopt | 26 | $11,150 | $429 |
| Prednisolone Acetate | 252 | $9,794 | $39 |
| Vyzulta | 13 | $5,841 | $449 |
| Zerviate | 12 | $4,459 | $372 |
| Lotemax Sm | 14 | $3,365 | $240 |
| Flarex | 25 | $3,260 | $130 |
| Brimonidine | 92 | $2,308 | $25 |
| Difluprednate | 15 | $2,257 | $150 |
| Dorzolamide-Timolol | 19 | $787 | $41 |
| Timolol Maleate | 48 | $620 | $13 |
| Atropine Sulfate | 12 | $508 | $42 |
| Latanoprost | 14 | $351 | $25 |
2021: 21 drugs
| Restasis | 338 | $346,531 | $1,025 |
| Dorzolamide | 660 | $25,126 | $38 |
| Cequa | 30 | $17,202 | $573 |
| Prolensa | 50 | $15,514 | $310 |
| Xiidra | 21 | $14,781 | $704 |
| Azopt | 30 | $14,739 | $491 |
| Simbrinza | 68 | $14,091 | $207 |
| Brinzolamide | 24 | $13,480 | $562 |
| Combigan | 38 | $11,708 | $308 |
| Rhopressa | 20 | $10,307 | $515 |
| Alphagan P | 24 | $7,527 | $314 |
| Eysuvis | 14 | $6,672 | $477 |
| Prednisolone Acetate | 76 | $3,885 | $51 |
| Brimonidine | 75 | $3,881 | $52 |
| Durezol | 14 | $2,927 | $209 |
| Lotemax Sm | 11 | $2,484 | $226 |
| Timolol Maleate | 36 | $803 | $22 |
| Olopatadine | 22 | $538 | $24 |
| Ketorolac Tromethamine | 12 | $372 | $31 |
| Latanoprost | 12 | $294 | $24 |
| Dorzolamide-Timolol | 13 | $219 | $17 |
2020: 15 drugs
| Restasis | 288 | $336,946 | $1,170 |
| Azopt | 55 | $28,057 | $510 |
| Dorzolamide | 565 | $21,592 | $38 |
| Cequa | 21 | $17,071 | $813 |
| Prolensa | 53 | $16,306 | $308 |
| Pazeo | 45 | $12,775 | $284 |
| Simbrinza | 57 | $12,645 | $222 |
| Combigan | 18 | $5,428 | $302 |
| Brimonidine | 88 | $5,350 | $61 |
| Rhopressa | 13 | $3,716 | $286 |
| Durezol | 13 | $2,547 | $196 |
| Olopatadine | 27 | $1,249 | $46 |
| Prednisolone Acetate | 27 | $1,115 | $41 |
| Liothyronine | 13 | $334 | $26 |
| Timolol Maleate | 25 | $281 | $11 |
2019: 17 drugs
| Restasis | 186 | $244,161 | $1,313 |
| Restasis Multidose | 39 | $32,913 | $844 |
| Dorzolamide | 453 | $16,790 | $37 |
| Prolensa | 44 | $16,323 | $371 |
| Azopt | 30 | $15,089 | $503 |
| Simbrinza | 76 | $14,822 | $195 |
| Pazeo | 48 | $11,470 | $239 |
| Combigan | 17 | $4,554 | $268 |
| Brimonidine | 66 | $3,927 | $60 |
| Alphagan P | 13 | $3,796 | $292 |
| Durezol | 13 | $2,912 | $224 |
| Prednisolone Acetate | 62 | $2,879 | $46 |
| Olopatadine | 43 | $2,746 | $64 |
| Lotemax | 12 | $2,374 | $198 |
| Pilocarpine | 14 | $986 | $70 |
| Timolol Maleate | 20 | $501 | $25 |
| Dorzolamide-Timolol | 12 | $443 | $37 |
2018: 19 drugs
| Restasis | 134 | $146,974 | $1,097 |
| Restasis Multidose | 155 | $121,391 | $783 |
| Simbrinza | 62 | $10,349 | $167 |
| Prolensa | 36 | $9,154 | $254 |
| Dorzolamide | 343 | $7,770 | $23 |
| Xiidra | 14 | $7,147 | $510 |
| Brimonidine | 65 | $6,525 | $100 |
| Pazeo | 33 | $6,036 | $183 |
| Combigan | 18 | $5,907 | $328 |
| Durezol | 22 | $4,121 | $187 |
| Lotemax | 17 | $3,446 | $203 |
| Bromfenac | 16 | $2,447 | $153 |
| Prednisolone Acetate | 51 | $2,258 | $44 |
| Lumigan | 12 | $2,169 | $181 |
| Olopatadine | 31 | $1,905 | $61 |
| Pilocarpine | 17 | $1,182 | $70 |
| Timolol Maleate | 14 | $605 | $43 |
| Dorzolamide-Timolol | 17 | $329 | $19 |
| Latanoprost | 16 | $138 | $9 |
2017: 16 drugs
| Restasis | 185 | $163,384 | $883 |
| Restasis Multidose | 50 | $33,729 | $675 |
| Simbrinza | 58 | $9,573 | $165 |
| Combigan | 35 | $7,996 | $228 |
| Dorzolamide | 347 | $7,733 | $22 |
| Lotemax | 35 | $6,865 | $196 |
| Prolensa | 28 | $6,647 | $237 |
| Brimonidine | 38 | $6,248 | $164 |
| Bromfenac | 24 | $5,149 | $215 |
| Pazeo | 30 | $4,974 | $166 |
| Alphagan P | 19 | $4,693 | $247 |
| Lumigan | 24 | $4,455 | $186 |
| Durezol | 26 | $4,166 | $160 |
| Prednisolone Acetate | 52 | $3,363 | $65 |
| Timolol Maleate | 17 | $1,713 | $101 |
| Latanoprost | 34 | $420 | $12 |
2016: 15 drugs
| Restasis | 250 | $208,928 | $836 |
| Prolensa | 69 | $14,796 | $214 |
| Combigan | 56 | $9,340 | $167 |
| Alphagan P | 25 | $6,647 | $266 |
| Lumigan | 29 | $5,910 | $204 |
| Brimonidine | 38 | $5,459 | $144 |
| Simbrinza | 36 | $5,346 | $149 |
| Lotemax | 30 | $4,817 | $161 |
| Bromfenac | 28 | $3,776 | $135 |
| Dorzolamide | 172 | $3,346 | $19 |
| Durezol | 21 | $3,257 | $155 |
| Prednisolone Acetate | 36 | $2,717 | $75 |
| Pazeo | 15 | $2,351 | $157 |
| Latanoprost | 99 | $1,116 | $11 |
| Ofloxacin | 13 | $290 | $22 |
2015: 17 drugs
| Restasis | 230 | $178,275 | $775 |
| Lotemax | 44 | $8,613 | $196 |
| Nevanac | 32 | $7,097 | $222 |
| Prolensa | 33 | $7,054 | $214 |
| Bromfenac | 37 | $5,411 | $146 |
| Lumigan | 19 | $3,710 | $195 |
| Brimonidine | 49 | $3,661 | $75 |
| Dorzolamide | 152 | $3,413 | $22 |
| Prednisolone Acetate | 37 | $3,278 | $89 |
| Combigan | 20 | $3,194 | $160 |
| Durezol | 20 | $3,050 | $152 |
| Latanoprost | 257 | $2,894 | $11 |
| Vigamox | 11 | $2,294 | $209 |
| Simbrinza | 19 | $2,202 | $116 |
| Pataday | 13 | $2,044 | $157 |
| Dorzolamide-Timolol | 23 | $553 | $24 |
| Timolol Maleate | 15 | $280 | $19 |
2014: 18 drugs
| Restasis | 162 | $98,486 | $608 |
| Prolensa | 40 | $8,632 | $216 |
| Nevanac | 35 | $6,689 | $191 |
| Brimonidine | 44 | $5,873 | $133 |
| Lotemax | 36 | $5,306 | $147 |
| Lumigan | 20 | $4,468 | $223 |
| Combigan | 23 | $3,406 | $148 |
| Bromfenac | 20 | $3,186 | $159 |
| Azopt | 16 | $2,623 | $164 |
| Latanoprost | 152 | $2,606 | $17 |
| Alphagan P | 16 | $2,242 | $140 |
| Prednisolone Acetate | 25 | $2,178 | $87 |
| Dorzolamide-Timolol | 66 | $2,124 | $32 |
| Pataday | 11 | $1,638 | $149 |
| Durezol | 11 | $1,467 | $133 |
| Azasite | 13 | $1,400 | $108 |
| Dorzolamide | 38 | $1,013 | $27 |
| Timolol Maleate | 26 | $257 | $10 |
2013: 12 drugs
| Restasis | 91 | $43,249 | $475 |
| Bromday | 47 | $8,366 | $178 |
| Nevanac | 26 | $4,605 | $177 |
| Lotemax | 34 | $4,554 | $134 |
| Pataday | 20 | $3,151 | $158 |
| Dorzolamide-Timolol | 72 | $2,326 | $32 |
| Brimonidine | 28 | $2,292 | $82 |
| Latanoprost | 104 | $1,925 | $19 |
| Combigan | 19 | $1,917 | $101 |
| Bromfenac | 17 | $1,878 | $110 |
| Prednisolone Acetate | 18 | $768 | $43 |
| Timolol Maleate | 31 | $303 | $10 |
Money from drug and device companies
$3,410 in 2025
| 2025 | 12 | 99 | None | $3,410 |
| 2024 | 11 | 89 | None | $2,462 |
| 2023 | 11 | 54 | None | $1,605 |
| 2022 | 13 | 37 | $173 | $1,943 |
| 2021 | 8 | 22 | None | $709 |
| 2020 | 7 | 22 | None | $308 |
| 2019 | 9 | 21 | None | $525 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biotissue Holdings | Prokera | $1,596 | 13 payments
|
| Alcon Vision | Tryptyr | $520 | 15 payments
|
| Amgen | Tepezza | $404 | 19 payments
|
| Tarsus Pharmaceuticals | Xdemvy | $329 | 37 payments
|
| Carl Zeiss Meditec USA | None | $135 | 2 payments
|
| Dompe US | Oxervate | $125 | 1 payment
|
See all 99 published payments
| Sun Pharmaceutical Industries | Meals · 2025-12-16 | Cequa | $33 |
| Alcon Vision | Meals · 2025-12-10 | Tryptyr | $26 |
| Amgen | Meals · 2025-12-09 | Tepezza | $30 |
| Tarsus Pharmaceuticals | Meals · 2025-12-09 | Xdemvy | $9 |
| Tarsus Pharmaceuticals | Meals · 2025-12-04 | Xdemvy | $9 |
| Apellis Pharmaceuticals | Meals · 2025-12-02 | Syfovre | $29 |
| Tarsus Pharmaceuticals | Meals · 2025-11-19 | Xdemvy | $9 |
| Sun Pharmaceutical Industries | Meals · 2025-11-18 | Cequa | $25 |
| Carl Zeiss Meditec USA | Meals · 2025-11-15 | None | $108 |
| Carl Zeiss Meditec USA | Meals · 2025-11-14 | None | $26 |
| Tarsus Pharmaceuticals | Meals · 2025-11-12 | Xdemvy | $8 |
| Amgen | Meals · 2025-11-11 | Tepezza | $8 |
| Tarsus Pharmaceuticals | Meals · 2025-11-05 | Xdemvy | $8 |
| Oyster Point Pharma | Meals · 2025-11-04 | Tyrvaya | $16 |
| Alcon Vision | Meals · 2025-10-30 | Tryptyr | $16 |
| Tarsus Pharmaceuticals | Meals · 2025-10-29 | Xdemvy | $8 |
| Amgen | Meals · 2025-10-23 | Tepezza | $10 |
| Sun Pharmaceutical Industries | Meals · 2025-10-21 | Cequa | $28 |
| Biotissue Holdings | Meals · 2025-10-08 | None | $62 |
| Alcon Vision | Meals · 2025-10-07 | Tryptyr | $24 |
| Tarsus Pharmaceuticals | Meals · 2025-10-02 | Xdemvy | $8 |
| Amgen | Meals · 2025-09-30 | Tepezza | $31 |
| Alcon Vision | Meals · 2025-09-26 | Tryptyr | $18 |
| Biotissue Holdings | Meals · 2025-09-26 | None | $129 |
| Tarsus Pharmaceuticals | Meals · 2025-09-23 | Xdemvy | $8 |
| Tarsus Pharmaceuticals | Meals · 2025-09-11 | Xdemvy | $8 |
| Oyster Point Pharma | Meals · 2025-09-10 | Tyrvaya | $15 |
| Alcon Vision | Meals · 2025-09-05 | Tryptyr | $13 |
| Amgen | Meals · 2025-08-27 | Tepezza | $29 |
| Tarsus Pharmaceuticals | Meals · 2025-08-27 | Xdemvy | $9 |
| Alcon Vision | Meals · 2025-08-21 | Tryptyr | $126 |
| Alcon Vision | Meals · 2025-08-16 | Eysuvis | $27 |
| Tarsus Pharmaceuticals | Meals · 2025-08-14 | Xdemvy | $7 |
| Bausch & Lomb Americas | Meals · 2025-08-12 | Xiidra | $20 |
| Biotissue Holdings | Meals · 2025-08-11 | None | $27 |
| Tarsus Pharmaceuticals | Meals · 2025-08-08 | Xdemvy | $8 |
| Amgen | Meals · 2025-08-05 | Tepezza | $6 |
| Biotissue Holdings | Meals · 2025-08-02 | None | $7 |
| Tarsus Pharmaceuticals | Meals · 2025-07-29 | Xdemvy | $5 |
| Regeneron Healthcare Solutions | Meals · 2025-07-24 | Eylea Hd | $37 |
| Tarsus Pharmaceuticals | Meals · 2025-07-17 | Xdemvy | $9 |
| Dompe US | Meals · 2025-07-17 | Oxervate | $125 |
| Biotissue Holdings | Meals · 2025-07-16 | None | $90 |
| Amgen | Meals · 2025-07-15 | Tepezza | $30 |
| Alcon Vision | Meals · 2025-07-10 | Eysuvis | $21 |
| Tarsus Pharmaceuticals | Meals · 2025-07-10 | Xdemvy | $26 |
| Alcon Vision | Meals · 2025-06-26 | Rhopressa | $125 |
| Amgen | Meals · 2025-06-26 | Tepezza | $8 |
| Tarsus Pharmaceuticals | Meals · 2025-06-26 | Xdemvy | $9 |
| Tarsus Pharmaceuticals | Meals · 2025-06-18 | Xdemvy | $8 |
| Alcon Vision | Meals · 2025-06-12 | Eysuvis | $18 |
| Amgen | Meals · 2025-06-11 | Tepezza | $31 |
| Bausch & Lomb Americas | Meals · 2025-06-11 | Xiidra | $22 |
| Tarsus Pharmaceuticals | Meals · 2025-06-10 | Xdemvy | $8 |
| Alcon Vision | Meals · 2025-06-06 | Eysuvis | $13 |
| Tarsus Pharmaceuticals | Meals · 2025-06-04 | Xdemvy | $8 |
| Amgen | Meals · 2025-05-28 | Tepezza | $30 |
| Tarsus Pharmaceuticals | Meals · 2025-05-28 | Xdemvy | $12 |
| Tarsus Pharmaceuticals | Meals · 2025-05-20 | Xdemvy | $7 |
| Alcon Vision | Meals · 2025-05-19 | Eysuvis | $9 |
| Tarsus Pharmaceuticals | Meals · 2025-05-14 | Xdemvy | $9 |
| Alcon Vision | Meals · 2025-05-13 | Rocklatan | $32 |
| Biotissue Holdings | Meals · 2025-05-08 | None | $107 |
| ViiV Healthcare | Meals · 2025-05-07 | Apretude | $14 |
| Amgen | Meals · 2025-05-06 | Tepezza | $12 |
| Tarsus Pharmaceuticals | Meals · 2025-04-24 | Xdemvy | $11 |
| Sun Pharmaceutical Industries | Meals · 2025-04-22 | Cequa | $33 |
| Tarsus Pharmaceuticals | Meals · 2025-04-19 | Xdemvy | $9 |
| Tarsus Pharmaceuticals | Meals · 2025-04-16 | Xdemvy | $6 |
| Tarsus Pharmaceuticals | Meals · 2025-04-16 | Xdemvy | $4 |
| Amgen | Meals · 2025-04-15 | Tepezza | $30 |
| Biotissue Holdings | Meals · 2025-04-05 | None | $130 |
| Tarsus Pharmaceuticals | Meals · 2025-04-03 | Xdemvy | $9 |
| Amgen | Meals · 2025-04-02 | Tepezza | $10 |
| Amgen | Meals · 2025-03-27 | Tepezza | $22 |
| Tarsus Pharmaceuticals | Meals · 2025-03-25 | Xdemvy | $9 |
| Biotissue Holdings | Meals · 2025-03-20 | None | $25 |
| Biotissue Holdings | Meals · 2025-03-19 | None | $30 |
| Amgen | Meals · 2025-03-18 | Tepezza | $30 |
| Tarsus Pharmaceuticals | Meals · 2025-03-18 | Xdemvy | $5 |
| Tarsus Pharmaceuticals | Meals · 2025-03-18 | Xdemvy | $4 |
| Tarsus Pharmaceuticals | Meals · 2025-03-12 | Xdemvy | $5 |
| Tarsus Pharmaceuticals | Meals · 2025-03-12 | Xdemvy | $5 |
| Apellis Pharmaceuticals | Meals · 2025-03-11 | Syfovre | $31 |
| Biotissue Holdings | Travel · 2025-03-08 | None | $393 |
| Biotissue Holdings | Meals · 2025-03-08 | Prokera | $199 |
| Biotissue Holdings | Meals · 2025-03-07 | Prokera | $272 |
| Alcon Vision | Meals · 2025-03-04 | Rocklatan | $19 |
| Amgen | Meals · 2025-02-18 | Tepezza | $29 |
| Tarsus Pharmaceuticals | Meals · 2025-02-13 | Xdemvy | $25 |
| Tarsus Pharmaceuticals | Meals · 2025-02-12 | Xdemvy | $10 |
| Amgen | Meals · 2025-02-06 | Tepezza | $10 |
| Alcon Vision | Meals · 2025-02-05 | Rocklatan | $32 |
| Amgen | Meals · 2025-01-29 | Pavblu | $18 |
| Tarsus Pharmaceuticals | Meals · 2025-01-29 | Xdemvy | $8 |
| Biotissue Holdings | Meals · 2025-01-26 | None | $125 |
| Amgen | Meals · 2025-01-21 | Tepezza | $30 |
| Tarsus Pharmaceuticals | Meals · 2025-01-15 | Xdemvy | $10 |
| Tarsus Pharmaceuticals | Meals · 2025-01-09 | Xdemvy | $9 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,462
| Biotissue Holdings | None | $846 | 14 payments
|
| Amgen | Tepezza | $666 | 24 payments
|
| Tarsus Pharmaceuticals | Xdemvy | $217 | 20 payments
|
| Apellis Pharmaceuticals | Syfovre | $203 | 5 payments
|
| Bausch & Lomb Americas | Xiidra | $200 | 13 payments
|
| Oyster Point Pharma | Tyrvaya | $97 | 4 payments
|
| Sun Pharmaceutical Industries | Cequa | $78 | 3 payments
|
| Astellas Pharma US | Izervay | $53 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $38 | 1 payment
|
| Alcon Vision | Rocklatan | $38 | 2 payments
|
| Harrow Eye | Vevye | $25 | 1 payment
|
2023: $1,605
| Horizon Therapeutics plc | Tepezza | $519 | 17 payments
|
| Sun Pharmaceutical Industries | Cequa | $309 | 9 payments
|
| Bausch & Lomb Americas | Miebo | $200 | 5 payments
|
| Oyster Point Pharma | Tyrvaya | $192 | 8 payments
|
| Astellas Pharma US | None | $143 | 4 payments
|
| Alcon Vision | Rocklatan | $66 | 3 payments
|
| Apellis Pharmaceuticals | Syfovre | $53 | 3 payments
|
| Biotissue Holdings | Prokera | $47 | 2 payments
|
| Novartis Pharmaceuticals | Xiidra | $26 | 1 payment
|
| Genentech USA | Vabysmo | $25 | 1 payment
|
| Thea Pharma | None | $25 | 1 payment
|
2022: $1,943
| BioTissue Holdings | Prokera | $898 | 4 payments
|
| Oyster Point Pharma | Tyrvaya | $300 | 9 payments
|
| Sun Pharmaceutical Industries | Cequa | $194 | 10 payments
|
| Notal Vision | None | $173 | 1 payment
|
| Carl Zeiss Meditec USA | Visumax | $124 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $58 | 3 payments
|
| Kala Pharmaceuticals | Inveltys | $55 | 3 payments
|
| EyePoint Pharmaceuticals US | Yutiq | $35 | 1 payment
|
| Thea Pharma | None | $24 | 1 payment
|
| Alcon Vision | Simbrinza | $23 | 1 payment
|
| Abbvie | Durysta | $23 | 1 payment
|
| Eyevance Pharmaceuticals | Flarex | $20 | 1 payment
|
| Vyera Pharmaceuticals | Daraprim | $17 | 1 payment
|
2021: $709
| Kala Pharmaceuticals | Eysuvis | $219 | 7 payments
|
| Tissuetech | Prokera | $175 | 2 payments
|
| Allergan | Restasis Multidose | $155 | 4 payments
|
| Sun Pharmaceutical Industries | Cequa | $85 | 4 payments
|
| Eyevance Pharmaceuticals | Tobradex St | $28 | 2 payments
|
| Abiomed | Impella | $20 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $16 | 1 payment
|
| Bausch & Lomb a division of Bausch Health US | Prolensa | $12 | 1 payment
|
2020: $308
| Sun Pharmaceutical Industries | Cequa | $178 | 15 payments
|
| Allergan | Restasis | $33 | 2 payments
|
| Bausch & Lomb a division of Bausch Health US | Lotemax Sm | $23 | 1 payment
|
| Eyevance Pharmaceuticals | Flarex | $23 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $21 | 1 payment
|
| Kala Pharmaceuticals | Inveltys | $16 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $14 | 1 payment
|
2019: $525
| Novartis Pharmaceuticals | Durezol | $223 | 8 payments
|
| Bausch & Lomb a division of Bausch Health US | None | $76 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $57 | 3 payments
|
| Shire North American Group | Xiidra | $39 | 2 payments
|
| Sun Pharmaceutical Industries | Bromsite | $38 | 2 payments
|
| Allergan | Combigan | $29 | 2 payments
|
| Eyevance Pharmaceuticals | Flarex | $24 | 1 payment
|
| Spark Therapeutics | Luxturna | $22 | 1 payment
|
| Alimera Sciences | Iluvien | $16 | 1 payment
|
Checkups this office reported
10 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Age-Related Macular Degeneration (AMD): Dilated Macular ExaminationAs Medicare defines this measure | 99% | 180 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 87%That's most of the people this applied to. | 117 |
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 100%That's most of the people this applied to. | 251 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 15%That's few of the people this applied to. Better on this measure. | 149 |
| Diabetic Macular Edema - Loss of Visual AcuityAs Medicare defines this measure | 100% | 22 |
| Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes CareAs Medicare defines this measure | 94% | 140 |
| Glaucoma Intraocular Pressure ReductionAs Medicare defines this measure | 87% | 1,119 |
| Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of CareAs Medicare defines this measure | 100% | 494 |
See the other 2 measures
| Risky medications in older adultsOlder patients given a medication that is risky at their age | 0%That's few of the people this applied to. Better on this measure. | 703 |
| Screening for High Blood Pressure and Follow-Up DocumentedAs Medicare defines this measure | 95% | 2,678 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
Professional record
- NPI
- 1487680328
- Licence
- CA G831730
- Trained
- George Washington University School of Medicine, 1992
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207WX0107X (207WX0107X)
- Mailing address
- 455 Oconnor Dr Ste 310, San Jose, CA, 95128
- NPI first listed
- 2006-06-23
- NPI last updated
- 2026-04-28
- NPI record certified
- 2026-04-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 9360 N Name Uno Ste 210, Gilroy, CA, 95020